89395-66-4

Usage

Uses

Used in Catalyst Applications:
Ru((CH3)2SO)4Cl2 is used as a catalyst in the field of synthetic chemistry for its ability to efficiently and selectively catalyze a wide range of organic reactions. Its primary application is in the oxidation of alcohols and other organic compounds, where it demonstrates high catalytic activity and selectivity.
Used in Medicinal Applications:
Ru((CH3)2SO)4Cl2 has been studied for its potential applications in medicine due to its unique properties. The exploration of its use in medicinal applications is ongoing, with the aim of leveraging its characteristics for therapeutic benefits.
Used in Materials Science Applications:
In the field of materials science, ruthenium sulfoxide is also being investigated for its potential use. Its distinctive electronic and chemical properties make it a candidate for developing new materials with specific functionalities or improved performance.

Upstream product

• 67-68-5 dimethyl sulfoxide 
• 194497-67-1 trans-RuCl₂(Me₂SO)4 
• 14898-67-0 ruthenium trichloride hydrate 
• 10025-69-1 tin(II) chloride dihdyrate 
• 194497-67-1 cis-{RuCl₂(Me₂SO)4} 
• 10049-08-8 ruthenium(III)chloride 
• 14898-67-0 ruthenium(III) chloride trihydrate 
• 118541-65-4 mer-trichlorotris(dimethylsulfoxide)ruthenium(III) 
• 63767-78-2 ruthenium trichloride 

Downstream Products

• 31790-57-5 {tris(4,4'-diphenyl-2,2'-bipyridine)ruthenium(II)}Cl₂ 
• 24162-09-2 Ru(phen)₃²⁺ 
• 112220-32-3 RuCl₂(OS(CH₃)2)(CH₃C(CH₂As(C₆H₅)2)3) 
• 67-68-5 dimethyl sulfoxide 
• 103500-17-0 [tris(μ-chloro)bis((triphos)ruthenium(II))] chloride 
• 172703-18-3 trans-RuCl2(κ4-N,N'-bis[o-(dipenylphosphino)benzylidene]-1,2-diaminoethane) 
• 114384-16-6 cis,cis,cis-ruthenium(II)(Cl)2(dimethylsulfoxid)2(RSU-3100)2 

Relevant academic research and scientific papers

Preparation method of ruthenium tetra(dimethyl sulfoxide) dichloride metalloorganic compound

The molecular formula of a ruthenium tetra(dimethyl sulfoxide) dichloride metalloorganic compound is RuCl2 (DMSO)4, and the preparation method comprises the following steps: adding dimethyl sulfoxideinto a ruthenium reagent, reacting for 12-48 hours at the temperature of 80-90 DEG C until yellow precipitate appears, filtering to obtain a yellow solid, washing the yellow solid with acetone and diethyl ether respectively, and airing in air to obtain the ruthenium tetra(dimethyl sulfoxide) dichloride metalloorganic compound RuCl2 (DMSO)4 containing the dimethyl sulfoxide ligand. Many ruthenium metal complexes with novel structures and special functional properties can be prepared through the ruthenium tetra(dimethyl sulfoxide) dichloride metalloorganic compound, and more possibilities are provided for design and construction of functional complexes. Good potential application is realized in the aspects of molecular-based magnetic materials, nonlinear optical materials, selective catalysis, molecular recognition, gas adsorption, photoelectric materials and the like.

Tris-heteroleptic ruthenium(II) polypyridyl complexes: Synthesis, structural characterization, photophysical, electrochemistry and biological properties

Three water-soluble tris-heteroleptic ruthenium(II) polypyridyl complexes [Ru(bpy)(phen)(bpg)]2+ (1), [Ru(bpy)(dppz)(bpg)]2+ (2), and [Ru(phen)(dppz)(bpg)]2+ (3) (where bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline, dppz = dipyrido[3,2-a:2′,3′-c] phenazine, bpg = 4b,5,7,7a-tetrahydro-4b,7a-epiminomethanoimino-6H-imidazo[4,5-f] [1,10] phenanthroline-6,13-dione) have been synthesized and characterized. Molecular structures of complexes 1 and 3 are confirmed by single crystal X-ray structure determination. Interaction of complexes 1–3 with DNA is explored by various spectroscopic techniques. The complexes 1–3 show solvent dependent photophysical properties. Complexes 2 and 3 show extensive “molecular light switch” effect for DNA. The complexes 1–3 are low toxic towards HeLa (human cervical cancer) and HL-60 (human promyelocytic leukemia) cell lines. Further, the cellular uptake of complexes 2 and 3 by cells shows that complexes mainly localised on the nucleus of the cells.

Nitro reduction-based fluorescent probes for carbon monoxide require reactivity involving a ruthenium carbonyl moiety

Recently, several arylnitro-based fluorescent CO probes have been reported. The design was based on CO's ability to reduce an arylnitro group for fluorescence turn-on. In this work, we assessed the response of three published arylnitro-based fluorescent C

Synthesis and Characterization of an Epidermal Growth Factor Receptor-Selective RuII Polypyridyl–Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy

There is a current surge of interest in the development of novel photosensitizers (PSs) for photodynamic therapy (PDT), as those currently approved are not completely ideal. Among the tested compounds, we have previously investigated the use of RuII

Synthesis, characterization and biological evaluation of ruthenium flavanol complexes against breast cancer

Four Ru(II) DMSO complexes (M1R-M4R) having substituted flavones viz. 3-Hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one (HL1), 3-Hydroxy-2-(4-nitrophenyl)-4H-chromen-4-one (HL2), 3-Hydroxy-2-(4-dimethylaminophenyl)-4H–chromen-4-one (HL3) and 3-Hydroxy-2-(4-chlorophenyl)-4H-chromen-4-one (HL4) were synthesized and characterized by elemental analysis, IR, UV–Vis, 1H NMR spectroscopies and ESI-MS. The molecular structures of the complexes were investigated by integrated spectroscopic and computational techniques (DFT). Both ligands as well as their complexes were screened for anticancer activities against breast cancer cell lines MCF-7. Cytotoxicity was assayed by MTT [3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay. All ligands and their complexes exhibited significant cytotoxic potential of 5–40?μM concentration at incubation period of 24?h. The cell cytotoxicity increased significantly in a concentration-dependent manner. In this series of compounds, HL2 (IC50 17.2?μM) and its complex M2R (IC50 16?μM) induced the highest cytotoxicity.

Synthesis, reactivities and anti-cancer properties of ruthenium(II) complexes with a thiaether macrocyclic ligand

Drug resistance and severe patient side-effects of Pt drugs have spurred research into other metal-based pharmaceuticals and recently Ru complexes have been identified as promising anti-cancer drugs. A series of RuIIcomplexes [RuX2([9]aneS3)(S-dmso)] (X = Cl, Br, I, S-dmso = sulfur-bound dimethylsulfoxide) containing the neutral face-capping sulfur macrocycle ligand, 1,4,7-trithiacyclononane ([9]aneS3) was synthesized, characterized and their substitution reactions and biological activities were investigated. While the iodido complex was not sufficiently soluble for detailed studies, [RuCl2([9]aneS3)(S-dmso)] and [RuBr2([9]aneS3)(S-dmso)] were investigated to determine whether there was a direct relationship between the rates of halido ligand substitution (determined by UV/vis spectroscopy and X-ray absorption spectroscopy) and anti-cancer activities. A two-stage halido substitution process occurred in HEPES buffer (pH 7.4, 310 K). The rate constants for chlorido substitution were a factor of two larger than for the bromido analogue ((4.5 ± 0.2) × 10?4and (1.5 ± 0.1) × 10?4s?1for the chlorido complex and (2.6 ± 0.2) × 10?4and (9.2 ± 0.1) × 10?5s?1for the bromido complex). The corresponding rate constants were a factor of two to three times larger in cell culture media, but the same trends were observed. There was also a third slower reaction in media that had the same rate constant irrespective of the starting complex ((3.6 ± 0.7) × 10?5and (3.9 ± 0.3) × 10?5s?1, respectively). Neither complex exhibited significant cytotoxicity. However, both complexes exhibited anti-invasive properties to highly invasive MDA-MB-231 breast cancer cells. The more reactive chlorido complex was also the most active in the invasion assay when either the cells were treated prior to the addition to collagen matrix, or the top collagen matrix was treated with Ru after adding it to cover the cells and wound.

An efficient route to asymmetrically diconjugated tris(heteroleptic) complexes of Ru(ii)

A highly efficient and versatile route to the preparation of tris(heteroleptic) Ru(ii) polypyridyl complexes is described which permits access to two or more independently conjugatable termini in the final structure. The strategy utilizes the well-known R

Anion receptor coordination tripods capped by [9]ane-S3

A series of ruthenium(ii) complexes with face-capping [9]ane-S3 ligands are described. The compounds function as supramolecular receptors for anions via three tripodally arranged 3-aminopyridine ligands. The [9]ane-S 3 ligand stabilises the tripodal complexes which are more readily prepared and studied than their π-arene ruthenium(ii) analogues. Pyrenyl derivative 4 displays some activity as a photophysical anion sensor but the anion response is complicated by the complexes concentration dependent emission behaviour. The receptors bind common anions in relatively polar media forming both 1:1 and 1:2 host-anion complexes with the CH...anion interactions involving the thioether ring being implicated in anion binding as well as the convention NH donors.

Multi-nuclear NMR investigation of nickel(II), palladium(II), platinum(II) and ruthenium(II) complexes of an asymmetrical ditertiary phosphine

Complexes synthesized by reacting alkyl and aryl phosphines with different transition metals are of great interest due to their catalytic properties. Many of the phosphine complexes are soluble in polar solvents as a result they find applications in homogeneous catalysis. In our present work we report, four transition metal complexes of Ni(II), Pd(II), Pt(II) and Ru(II) with an asymmetrical ditertiaryphosphine ligand. The synthesized ligand bears a less electronegative substituent such as methyl group on the aromatic nucleus hence makes it a strong ω-donor to form stable complexes and thus could effectively used in catalytic reactions. The complexes have been completely characterized by elemental analyses, FTIR, 1HNMR, 31PNMR and FAB Mass Spectrometry methods. Based on the spectroscopic evidences it has been confirmed that Ni(II), Pd(II) and Pt(II) complexes with the ditertiaryphosphine ligand showed cis whereas the Ru(II) complex showed trans geometry in their molecular structure.

[RuCl2(η6-p-cymene)(P*)] and [RuCl 2(κ-P-η6-arene)] complexes containing p -stereogenic phosphines. activity in transfer hydrogenation and interactions with DNA

The preparation of a series of half-sandwich ruthenium complexes, [RuCl2(η6-p-cymene)(P)] (P* = S-PMeRR′) and [RuCl2(κ-P-η6-arene)], containing P-stereogenic phosphines is reported. The borane-protected P-stereogenic phosphines have been obtained by addition of the (H3B)PMe 2R (R = t-Bu (1), Cy (2), Fc (3))/sec-BuLi/(-)-sparteine adduct to benzyl halides, carbonyl functions, and epoxides with yields between 40 and 90% and ee values in the 70-99% range. Those containing an aryl secondary function have been used in the preparation of [RuCl2(η6-p- cymene)(P)] complexes. Borane deprotection has been performed using HBF 4, except for (H3B)PRMe(CH2SiMe2Ph) phosphines, where DABCO was used to avoid partial cleavage of the CH 2-Si bond. In the case of (H3B)P(t-Bu)Me(CH 2C(OH)Ph2) (1l) the dehydrated phosphine was obtained. The tethered complexes were obtained by p-cymene substitution in chlorobenzene at 120 C, except for ferrocenyl-containing complexes, which decomposed upon heating. The presence of substituents in the aryl arm of some of the phosphines introduces new chiral elements in the tethered [RuCl2(κ-P- η6-arene)] compounds. Full characterization of all compounds both in solution and in the solid state has been carried out. Crystal structure determinations of four phosphine-borane molecules confirm the S configuration at the phosphorus atom (1a,e,l and 2d). Moreover, the crystal structure of one p-cymene complex (5i) and four tethered complexes reveal the strain of the compounds with two atoms in the tether (7c,g,l and 8i). Tethering has a marked effect on the catalytic performance transfer hydrogenation of acetophenone and on the nature of hydridic species originating during the activation period. The chiral induction attains 58% ee with complexes with the bulkiest substituents in the pendant arm of the phosphine. Three of the prepared complexes can interact with DNA and present a reasonable cytotoxicity toward cancer cells. Intercalation of the free aromatic pendant arm of the phosphines seems to be fundamental for such interactions.